DALLAS: AleraCare and PURE Healthcare, two leading providers of infusion and specialty pharmacy services, announced Thursday that they have entered into a definitive merger agreement. The merger aims to expand access to high-quality patient care and lower the overall cost of healthcare for individuals with complex chronic and autoimmune conditions.
Terms of the transaction were not disclosed. The merger is expected to close in the fourth quarter of 2025, pending regulatory approvals.
AleraCare, founded in 2019, provides services through ambulatory infusion centers, home infusion therapy and specialty pharmacy. The company operates more than 30 ambulatory infusion centers across the U.S. and focuses on serving patients with complex medical needs.
PURE Healthcare, established in 2018, specializes in treating chronic and autoimmune conditions like rheumatoid arthritis, multiple sclerosis and Alzheimer’s disease. Its flagship offering, Pure Infusion Suites, has 43 locations across 14 states, which offer personalized, patient-centered care and aim to make infusion therapy more affordable.
The combined company is expected to leverage both organizations’ strengths to improve clinical outcomes and expand the availability of infusion services.
Holland & Knight is serving as legal counsel for AleraCare. Kunzler Bean & Adamson is serving as legal counsel and Cantor Fitzgerald is acting as financial advisor for PURE Healthcare.